Your browser doesn't support javascript.
Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study.
Martín-Bravo, Celia; Quirós, Raúl; Blancas, Isabel; Villatoro-Roldán, Rosa; Robles, Marta; Alcaide, Julia; Navarro, Víctor; Pérez, Diego; Zarcos, Irene; Rivas-Ruiz, Francisco; Pérez-Ruiz, Elisabeth; Quero, Cristina.
  • Martín-Bravo C; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga. Electronic address: celiam1994@hotmail.com.
  • Quirós R; Medicine Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga; Research Network on Health Services in Chronic Diseases (REDISSEC), Marbella, Málaga. Electronic address: quiroslopez77@gmail.com.
  • Blancas I; Oncology Department, San Cecilio Clinical Hospital, Granada, Spain. Avenida del Conocimiento, s/n, 18016 Granada. Electronic address: iblancas@ugr.es.
  • Villatoro-Roldán R; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga. Electronic address: villatororoldan@gmail.com.
  • Robles M; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga. Electronic address: mrobleslasarte@gmail.com.
  • Alcaide J; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga; Research Network on Health Services in Chronic Diseases (REDISSEC), Marbella, Málaga. Electronic address: drayulia@hotmail.com.
  • Navarro V; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga. Electronic address: victor.navarr1@gmail.com.
  • Pérez D; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga. Electronic address: dipema2026@gmail.com.
  • Zarcos I; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga; Research Network on Health Services in Chronic Diseases (REDISSEC), Marbella, Málaga. Electronic address: irenezarcos@hotmail.com.
  • Rivas-Ruiz F; Research Unit, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga; Research Network on Health Services in Chronic Diseases (REDISSEC), Marbella, Málaga. Electronic address: frivasr@hcs.es.
  • Pérez-Ruiz E; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga; Biomedical Research Institute of Málaga (IBIMA), Málaga, Spain. St. Dr. Miguel Díaz Recio, 28, 29010 Málaga; Research Network on Health Services in Chronic Diseases (REDISSEC), Marbella, Málaga. Electr
  • Quero C; Oncology Department, Costa del Sol Hospital, Marbella, Spain. A-7, Km 187, 29603 Marbella, Málaga. Electronic address: cquerob@gmail.com.
Semin Oncol ; 48(2): 145-151, 2021 04.
Article in English | MEDLINE | ID: covidwho-1174725
ABSTRACT

BACKGROUND:

Leading scientific societies have recommended delaying and/or suspending active cancer treatment during the COVID-19 pandemic. Nevertheless, data on this novel infection in patients with a diagnosis of cancer receiving active treatment are scarce and it is unknown if these recommendations could have repercussions on future progress of the disease. The main objective of this study is to learn the COVID-19 incidence rate in outpatients with cancer receiving active treatment.

METHODS:

This work is a retrospective cohort study that included all patients with a diagnosis of cancer who received active cancer treatment in two Andalusian hospitals between February 26 and May 13, 2020. Variables regarding the patient, tumor, and development of COVID-19 were collected. A descriptive analysis was performed and the cumulative incidence of COVID-19 in these patients was evaluated.

RESULTS:

A total of 673 patients were included. The median age was 62 years. There was a low rate of comorbidity and 12.1% had an ECOG >2. Breast cancer was the most common cancer (41%), followed by colorectal and lung cancer. Stage IV cancer was reported in 52.7% of patients. The most common treatment was chemotherapy (53.9%). Treatment was delayed or suspended in 6% of patients. Only three patients developed COVID-19. The cumulative incidence was 0.44% and one person died due to infection.

CONCLUSIONS:

In the present retrospective cohort study we found a low incidence of COVID-19 infection in patients with cancer receiving active treatment in an outpatient setting. The sociodemographic factors of Andalusia may explain why these results differ from those presented by other colleagues in Spain, but raise questions about whether universal recommendations may put the benefits of antineoplastic therapy at risk.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Outpatients / SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Semin Oncol Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Outpatients / SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Semin Oncol Year: 2021 Document Type: Article